大脑粉样血管病变和下游阿尔茨海默病 血生物标志物
Sung Hoon Kang1,2, Eun Hye Lee1,3,4, Young Ju Kim1,5
1Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
JAMA network open
|May 9, 2025
概括
大脑粉样血管病变 (CAA) 成像标志物与阿尔茨海默病 (AD) 血生物标志物有关,影响认知能力下降. 这些发现对于监测接受粉素向治疗的患者至关重要.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 医疗成像医学成像
背景情况:
- 大脑粉样蛋白血管病变 (CAA) 是粉样蛋白相关成像异常的一个关键风险因素.
- 随着粉样蛋白向治疗的可用性,监测CAA变得越来越重要.
- 关于阿尔茨海默病 (AD) 血生物标志物和CAA成像标志物之间的关联,存在有限的证据.
研究的目的:
- 研究CAA成像标记物和下游AD血生物标记物之间的关系.
- 评估粉样蛋白-β (Aβ) 吸收在这些关联中对PET的作用.
- 为了确定CAA标记物和AD生物标记物之间的相互作用是否会影响认知变化.
主要方法:
- 一项基于注册的队列研究,涉及1708名45岁以上的参与者,来自韩国25家医院.
- 通过MRI评估CAA成像标记物 (CMBs,皮质表面 siderosis 等. ) 的情况.
- 测量血生物标志物 (p-tau217,GFAP,NfL) 和粉样β (Aβ) PET成像.
主要成果:
- 脑微血流 (CMB) 和CAA存在与高的p-tau217,GFAP和NfL水平相关,部分由Aβ PET吸收介导.
- 高血压动脉硬化标志物 (缺口,深CMBs) 与NfL水平相关.
- 叶片CMB和p-tau217/GFAP水平之间的相互作用与认知能力下降有关.
结论:
- 在CAA成像标记物,AD血生物标记物和与Aβ负担相关的认知衰退之间发现了一种新的关联.
- 这些发现突显了CAA成像标志物的临床意义,特别是关于粉样蛋白相关的成像异常.
- 了解这些关联对于管理接受新的粉样蛋白向治疗的患者至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
328
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
328
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
03:03Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K